Top Stocks to Watch for January 07, 2014 (NASDAQ: CTIC) (TSX:MBX)

Cell Therapeutics Inc (NASDAQ: CTIC), a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer, gained over 25% during its past two trading sessions gaining more than 11% in each of the two consecutive days. During its last trading session, the stock gained 12.7% and closed at its 52-week high of $2.48 with significant trading volume of 20.1 million shares. During its past 5-trading sessions, CTIC gained 32.6% with 5-day average volume of 7.4 million shares compared to 1-month daily average volume of 2.8 shares. The stock jumped after National Institute for Health and Care Excellence (NICE) issued positive Final Appraisal Determination (FAD) for CTIC’s PIXUVRI, a treatment for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. After the approval, the physicians in the U.K will soon have access to the drug as a third or fourth-line treatment option for patients. The company anticipates launching Pixuvri in England sometime in the early spring.

Microbix Biosystems Inc (TSX: MBX), a Canada-based biotechnology company engaged in research and development, and commercialization of biological products and technologies, gained over 56% during its past two trading sessions gaining more than 25% in each of the two consecutive days. During its last trading session, the stock gained 25% and closed at its 52-week high of C$0.25 with significant trading volume of 179,600 shares. During its past 5-trading sessions, MBX gained 66.7% with 5-day average volume of 72,609 shares compared to 1-month daily average volume of 42,197 shares. Yesterday, MBX sued Novartis Vaccines and Diagnostics alleging infringement of its proprietary VIRUSMAX technology. VIRUSMAX technology is useful for increasing virus yields in egg-based vaccine manufacture.